Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum

Journal of Neural Transmission

Volumn 109, Issue 3, 2002, Pages 239-249

  Wu, H Q ^a   Rassoulpour, A ^a   Schwarcz, R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytes; Dopamine; Excitotoxicity; Kynurenic acid; Nigrostriatal; Parkinson's disease; Quinolinic acid

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMIC ACID; KYNURENIC ACID; LEVODOPA; OXIDOPAMINE; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN LEVEL; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DOSE TIME EFFECT RELATION; DRUG EFFECT; MALE; MICRODIALYSIS; NEUROMODULATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION;

ANIMALS; ASTROCYTES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXTRACELLULAR SPACE; KYNURENIC ACID; LEVODOPA; MALE; NEOSTRIATUM; NEURONS; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SUBSTANTIA NIGRA;

EID: 0036202546     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200020     Document Type: Article

References (57)

1. Kynurenine pathway measurements in Huntington's disease: Evidence for reduced formation of kynurenic acid
2. Short- and long-term consequences of intracranial injections of the excitotoxin quinolinic acid as evidenced by GFA immunohistochemistry of astrocytes
3. A synaptic model of memory: Long-term potentiation in the hippocampus
4. Acetylcholine-mediated modulation of striatal function
5. Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?
6. Trying to understand the brain's chemical language
7. Presynaptic kynurenate-sensitive receptors inhibit glutamate release
8. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum
9. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats
10. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal Huntington disease gene
11. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
12. Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication
13. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia
14. Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome
15. Nicotine-induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid
16. A receptor agonist muscimol is mediated via release of glutamate
17. The basal ganglia
18. Brain-specific modulation of kynurenic acid synthesis in the rat
19. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients
20. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid
21. The brain metabolite kynurenic acid blocks α7 nicotinic acetylcholine receptors in rat hippocampal neurons in culture
22. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: Reversal by lactate and pyruvate
23. From dopamine to Parkinson's disease: A personal research record
24. Neuronal cell death in Huntington's disease: A potential role for dopamine
25. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: Focus on kynurenine aminotransferases
26. Nicotinic receptors in the brain: Correlating physiology with function
27. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation
28. An astroglia-linked dopamine D2-receptor action in prefrontal cortex
29. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia
30. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients
31. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism
32. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid
33. Presence of kynurenic acid in the mammalian brain
34. Kynurenine pathway abnormalities in Parkinson's disease
35. Excitotoxicity of L-dopa and 6-OH-dopa: Implications for Parkinson's and Huntington's diseases
36. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase
37. Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors
38. The "kynurenate test", a biochemical assay for putative cognition enhancers
39. Dopaminergic control of kynurenate levels and NMDA toxicity in the developing rat striatum
40. Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats
41. Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain
42. Regulation of kynurenic acid synthesis and neuronal vulnerability to NMDA by acute administration of methylphenidate
43. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase
44. Quinolinic acid: An endogenous metabolite that causes axon-sparing lesions in rat brain
45. Quinolinic acid and kynurenic acid: Glia-derived modulators of excitotoxic brain injury
46. Modulation and function of kynurenic acid in the immature rat brain
47. (R,S)-3,4-dichloro-benzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats
48. Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents
49. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease
50. Neuropharmacology of quinolinic and kynurenic acid
51. D1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervation
52. Identification and quantification of kynurenic acid in human brain tissue
53. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine
54. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system
55. Kynurenic acid in the quinolinate-lesioned rat hippocampus: Studies in vitro and in vivo
56. Systemic L-DOPA causes a decrease of endogenous kynurenic acid levels in the rat striatum
57. Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture